What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

56 citing papers in PubMed, 66 citations in OpenAlex.

1. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.American journal of hematology · 2022
   Trial
2. The TP53 gene contains a diversity box that makes it more than a tumor suppressor.Cell death and differentiation · 2026
   Review
3. The Dynamic Alliance of p53 and Metabolism in the Tumor Microenvironment Shapes Tumor Evolution.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
   Review
4. The p53 Isoforms as Potential Biomarkers in Different Cancer Entities.International journal of molecular sciences · 2026
   Review
5. p53 Isoforms as Modifiers of the p53-Dependent Responses: A Hidden Code?Cancers · 2026
   Review
6. Regulation of oncogenic C-terminal truncated p53β protein isoform expression by SRSF3-UPF1 splicing and surveillance axis.Cell & bioscience · 2026
   Article
7. Structural potential of the 5' noncoding regions of the mRNAs encoding p53 isoforms.Acta biochimica Polonica · 2026
   Review
8. Δ133p53 isoform enhances TLR4 function to promote tumor growth.Carcinogenesis · 2025
   Article
9. p53 isoforms have a high aggregation propensity, interact with chaperones and lack binding to p53 interaction partners.eLife · 2025
   Article
10. NOTCH1 dimeric signaling is essential for T-cell leukemogenesis and leukemia maintenance.Blood · 2025
    Article
11. Aberrant Splicing as a Mechanism for Resistance to Cancer Therapies.Cancers · 2025
    Review
12. Widespread variation in molecular interactions and regulatory properties among transcription factor isoforms.Molecular cell · 2025
    Article
13. Interaction of p53 with the Δ133p53α and Δ160p53α isoforms regulates p53 conformation and transcriptional activity.Cell death & disease · 2024
    Article
14. Re-appraising the evidence for the source, regulation and function of p53-family isoforms.Nucleic acids research · 2024
    Review
15. Germline variant affecting p53β isoforms predisposes to familial cancer.Nature communications · 2024
    Article
16. Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance.Cell death & disease · 2024
    Review
17. Widespread variation in molecular interactions and regulatory properties among transcription factor isoforms.bioRxiv : the preprint server for biology · 2024
    Article
18. Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential.Frontiers in cell and developmental biology · 2024
    Review
19. It is not all about the alpha: elevated expression of p53β variants is associated with lower probability of survival in a retrospective melanoma cohort.Cancer cell international · 2023
    Article
20. p53 Dysregulation in Breast Cancer: Insights on Mutations in theInternational journal of molecular sciences · 2023
    Article

Corrections and comments

• Erratum issued
  Correction:2025

Authors and funding

20 authors at 4 institutions in 3 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as